Search
SOLACI Congress
HomeFilePharmacology

Pharmacology

View Category

Other

ACC 2023 | A DUE-Study (Phase III)

In pulmonary hypertension (PHT), 10 mg macitentan plus 40 mg tadalafil is recommended as a safe combination therapy for...
solaci -
Learn More
Chronic Ischemic cardiopathy

ACC 2023 | YELLOW III Study. Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease

Dr. Kini presented the results of the YELLOW III Study where she analyzed the effect of evolocumab...
solaci -
Learn More
Acute coronary syndromes

Rivaroxaban in Acute Coronary Syndrome

Acute coronary syndromes (ACS) involve high mortality risk, especially ST elevation ACS. Their treatment is based on...
solaci -
Learn More
Acute coronary syndromes

Monotherapy with P2Y12 in Complex Interventions: Less and Less Risky

 Monotherapy in patients with complex angioplasty: meta-analysis of 5 randomized studies.  Even though prolonged dual antiplatelet therapy (DAPT)...
solaci -
Learn More
Antiplatelet

Is Using Drug-Eluting Balloons and Single Antiplatlelet Therapy Safe for Patients at High Risk for Bleeding Who Undergo Percutaneous Coronary Intervention?

The safety and efficacy of drug-coated balloons (DCB) has been established for the treatment of in-stent restenosis...
solaci -
Learn More
Antiplatelet

Is it Possible to Reduce DAPT Time in Diabetic Patients?

Short-duration dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with DES is growing steadily, especially for...
solaci -
Learn More
Acute coronary syndromes

Can We Use DAPT for 3 Months in Acute Coronary Syndrome?

Current guidelines recommend 12-month dual antiplatelet therapy (DAPT) after DES stenting for acute coronary syndrome (ACS) because...
solaci -
Learn More
Antithrombotic Anticoagulants

Is Clopidogrel Monotherapy Safe After a Month of Dual Antiplatelet Therapy in Diabetic Patients?

Currently, many randomized studies have suggested that short-term dual antiplatelet therapy (DAPT) followed by monotherapy reduces bleeding...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

Dr. Omar Tupayachi - 0
In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Dr. Omar Tupayachi - 0
Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Dr. Omar Tupayachi - 0
Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...

Institutional News

How to apply for the SOLACI Research 2025 Grant? Step-by-step explanation video

solaci - 0
You can now rewatch the virtual event we held on April 9th, where we thoroughly reviewed the steps to apply for the SOLACI Research...

April 9 – How to Apply for the SOLACI Research Grant 2025? Virtual Zoom Event

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event hosted by the SOLACI Research Department, aimed at clarifying doubts,...

Watch our event on Evidence and Controversies of Renal Denervation in 2025

solaci - 0
You can now watch our event, held in collaboration with Medtronic, titled "Evidence and Controversies of Renal Denervation in 2025." The event featured international experts...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy